PURPOSE: The purpose of this study was to evaluate the reliability of positron emission tomography (PET) in patients with follicular lymphoma (FL) after induction treatment. PATIENTS AND METHODS: In all, 45 previously untreated patients with FL were studied with PET and computed tomography (CT) scans after chemotherapy induction treatment (fludarabine-containing regimens and CHOP [cyclophosphamide/doxorubicin/vincristine/prednisone] chemotherapy). Histopathologic analysis was performed when considered necessary. RESULTS: After treatment, 4 of 5 patients (80%) who had CT-negative/PET-positive findings experienced relapse/progression, compared with only 1 of 22 patients (4.5%) in the CT-negative/PET-negative subset. Among the 18 patients with CT-positive findings, all 6 patients (100%) who had PET-positive findings experienced relapse or progression, compared with 1 of 12 patients (8.3%) who had PET-negative findings. The 2-year progression-free survival rates were 20% and 90% in the CT-negative/PET-positive and CT-positive/PET-negative subsets, respectively (P = 0.0031). During the follow-up, 2 patients, who presented a PET positivity with a negative CT scan, underwent a lymph node biopsy, which confirmed the presence of FL infiltration. CONCLUSION: In patients with FL, persisting PET positivity is predictive of early disease progression, because it is still highly likely that patients with PET-negative findings will ultimately progress, but this has not yet been manifested during the period of observation.
PURPOSE: The purpose of this study was to evaluate the reliability of positron emission tomography (PET) in patients with follicular lymphoma (FL) after induction treatment. PATIENTS AND METHODS: In all, 45 previously untreated patients with FL were studied with PET and computed tomography (CT) scans after chemotherapy induction treatment (fludarabine-containing regimens and CHOP [cyclophosphamide/doxorubicin/vincristine/prednisone] chemotherapy). Histopathologic analysis was performed when considered necessary. RESULTS: After treatment, 4 of 5 patients (80%) who had CT-negative/PET-positive findings experienced relapse/progression, compared with only 1 of 22 patients (4.5%) in the CT-negative/PET-negative subset. Among the 18 patients with CT-positive findings, all 6 patients (100%) who had PET-positive findings experienced relapse or progression, compared with 1 of 12 patients (8.3%) who had PET-negative findings. The 2-year progression-free survival rates were 20% and 90% in the CT-negative/PET-positive and CT-positive/PET-negative subsets, respectively (P = 0.0031). During the follow-up, 2 patients, who presented a PET positivity with a negative CT scan, underwent a lymph node biopsy, which confirmed the presence of FL infiltration. CONCLUSION: In patients with FL, persisting PET positivity is predictive of early disease progression, because it is still highly likely that patients with PET-negative findings will ultimately progress, but this has not yet been manifested during the period of observation.
Authors: Ludovic Le Dortz; Sophie De Guibert; Sahar Bayat; Anne Devillers; Roch Houot; Yan Rolland; Marc Cuggia; Florence Le Jeune; Haïfa Bahri; Marie-Luce Barge; Thierry Lamy; Etienne Garin Journal: Eur J Nucl Med Mol Imaging Date: 2010-08-18 Impact factor: 9.236
Authors: Ida Wong-Sefidan; Michelle Byrtek; Xiaolei Zhou; Jonathan W Friedberg; Christopher R Flowers; Andrew D Zelenetz; Keith L Dawson; Erin Reid Journal: Leuk Lymphoma Date: 2016-08-12
Authors: Barbara W Grant; Sin-Ho Jung; Jeffrey L Johnson; Lale Kostakoglu; Eric Hsi; John C Byrd; Jeffrey Jones; John P Leonard; S Eric Martin; Bruce D Cheson Journal: Cancer Date: 2013-08-06 Impact factor: 6.860